3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 1
2
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Gastrointestinal
2
Breast
2
Genitourinary
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
58
Lung Neoplasms
13
Colorectal Neoplasms
11
Neoplasms
8
Mesothelioma, Malignant
7
Mesothelioma
7
Meningeal Carcinomatosis
7
Neoplasm Metastasis
6
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Melanoma
4
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Gastrointestinal Neoplasms
3
Carcinoma, Transitional Cell
3
Advanced Solid Tumors
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Neoplasms by Site
2
NSCLC
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Carcinoma
2
Advanced Solid Tumor
2
Urologic Neoplasms
1
Solitary Fibrous Tumor, Pleural
1
Rectal Neoplasms
1
Interventions
pembrolizumab
30
Nivolumab
15
Paclitaxel
13
Cyclophosphamide
12
Carboplatin
12
sacituzumab govitecan
8
Cisplatin
8
Capecitabine
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
fludarabine
5
durvalumab
5
avelumab
5
atezolizumab
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
5
Biopsy
5
camrelizumab
4
Specimen Handling
4
Interleukin-2
4
Injections
4
Immune Checkpoint Inhibitors
4
Docetaxel
4
toripalimab
3
talazoparib
3
Leucovorin
3
Everolimus
3
Clinical Trials, Phase II as Topic
3
Bevacizumab
3
yeast-CEA vaccine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Triple Negative Breast Neoplasms
×
Pemetrexed
×
Clear all
NCT03267316
2024-08-22
CANFOUR
Cantargia AB
Phase 1/2
Completed
167 enrolled
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts